Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The minerals exploration and development Company announces that its joint venture partner in the Elizabeth Hill Silver Project, West Coast Silver Limited (ASX: WCE), has today announced its H2 2026 diamond drilling program at the high-grade Elizabeth Hill Silver Project in Western Australia is scheduled to commence in early to midOctober.</li>
<li>The 18 diamond hole drill program for ~1,800m is commencing across the Elizabeth Hill Silver Project, aiming to advance mineral resource definition, extension and new highgrade zone definition commenced in H1 2026.</li>
<li>West Core Drilling is scheduled to mobilise in the week of 5 October, with drilling expected to continue through early to mid-December. </li>
</ul>


The minerals exploration and development Company announces that its joint venture partner in the Elizabeth Hill Silver Project, West Coast Silver Limited (ASX: WCE), has today announced its H2 2026 diamond drilling program at the high-grade Elizabeth Hill Silver Project in Western Australia is scheduled to commence in early to midOctober.
The 18 diamond hole drill program for ~1,800m is commencing across the Elizabeth Hill Silver Project, aiming to advance mineral resource definition, extension and new highgrade zone definition commenced in H1 2026.
West Core Drilling is scheduled to mobilise in the week of 5 October, with drilling expected to continue through early to mid-December. 


<ul>
<li>The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech announces that the earn-out conditions in respect of its acquisition of IVDeology Holdings Ltd, originally announced on 7 May 2024, have been satisfied.</li>
<li>Pursuant to the terms of the share purchase agreement, earn-out consideration of £200k has become payable following the achievement of the maximum revenue target for the two-year earn-out period following acquisition.</li>
<li>Accordingly, the Earn-out Consideration will be satisfied by the issue of new ordinary shares in the Company to the vendors, Stuart Angell and Nancy Consterdine.</li>
</ul>


The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech announces that the earn-out conditions in respect of its acquisition of IVDeology Holdings Ltd, originally announced on 7 May 2024, have been satisfied.
Pursuant to the terms of the share purchase agreement, earn-out consideration of £200k has become payable following the achievement of the maximum revenue target for the two-year earn-out period following acquisition.
Accordingly, the Earn-out Consideration will be satisfied by the issue of new ordinary shares in the Company to the vendors, Stuart Angell and Nancy Consterdine.


<ul>
<li>The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech is awarded a series of contracts worth around £4.8m.</li>
<li>The contracts are with a US-based customer to develop and scale up to manufacture several multiplex quantitative lateral flow assay systems measuring multiple biomarkers simultaneously in human samples.</li>
<li>The agreed scope of work and will be delivered over circa 27-months commencing immediately and will be executed via a series of work packages with potential further contracts including the appointment as legal manufacturer. </li>
</ul>


The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech is awarded a series of contracts worth around £4.8m.
The contracts are with a US-based customer to develop and scale up to manufacture several multiplex quantitative lateral flow assay systems measuring multiple biomarkers simultaneously in human samples.
The agreed scope of work and will be delivered over circa 27-months commencing immediately and will be executed via a series of work packages with potential further contracts including the appointment as legal manufacturer. 


<ul>
<li>Abingdon Health 8.50p £20.09m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech wins a significant contract.</li>
<li>The Services Agreement is with a UK-based customer and has an expected value of approximately $2.5m to provide project management and expert technical support for the development and regulatory submission of a clinical self-test.</li>
<li>This will be across three key phases: Feasibility, Design &amp; Development and Verification &amp; Validation. </li>
</ul>


Abingdon Health 8.50p £20.09m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech wins a significant contract.
The Services Agreement is with a UK-based customer and has an expected value of approximately $2.5m to provide project management and expert technical support for the development and regulatory submission of a clinical self-test.
This will be across three key phases: Feasibility, Design &amp; Development and Verification &amp; Validation. 


<ul>
<li>The developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech reports for FY June 2025.</li>
<li>Revenue increased 40% to £8.6m, which included a grant and contribution from the acquired CS Lifesciences.</li>
<li>The EBITDA loss increased to £3.5m from a loss of £1.4m. Operational highlights include a $2m US contract win for the development of STD tests running 2026. </li>
</ul>


The developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech reports for FY June 2025.
Revenue increased 40% to £8.6m, which included a grant and contribution from the acquired CS Lifesciences.
The EBITDA loss increased to £3.5m from a loss of £1.4m. Operational highlights include a $2m US contract win for the development of STD tests running 2026. 


Hybridan Small Cap Feast: 11 November 2025

United Kingdom

Abingdon Health is an international developer, manufacturer, and distributor of lateral flow assay diagnostic tests, also known as rapid tests. The company provides comprehensive contract development and manufacturing (CDMO) services for rapid diagnostics across various sectors, including healthcare, animal health, and environmental testing. Abingdon Health is headquartered in York, England, and was founded in 2008.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abingdon Health (ABDX LN)

Small Cap Feast: 29 September 2026

West Core Drilling is scheduled to mobilise in the week of 5 October, with drilling expected to continue through early to mid-December.

Hybridan

Hybridan Small Cap Feast: 19 May 2026

Accordingly, the Earn-out Consideration will be satisfied by the issue of new ordinary shares in the Company to the vendors, Stuart Angell and...

Hybridan

Hybridan Small Cap Feast: 30 March 2026

The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech is awarded a series of contracts...

Hybridan

Hybridan Small Cap Feast: 12 March 2026

Abingdon Health 8.50p £20.09m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech wins a...

Hybridan

Hybridan Small Cap Feast: 11 November 2025

The developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech reports for FY June 2025. Revenue increased...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)